AbCellera Biologics, Inc. (ABCL)
| Market Cap | 5.89B |
| Revenue (ttm) | 447.65M |
| Net Income (ttm) | n/a |
| Shares Out | 278.70M |
| EPS (ttm) | 0.74 |
| PE Ratio | 28.58 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,663,151 |
| Open | 21.00 |
| Previous Close | 21.15 |
| Day's Range | 20.76 - 21.31 |
| 52-Week Range | 14.51 - 71.91 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 45.40 (+114.7%) |
| Est. Earnings Date | Nov 11, 2021 |
About ABCL
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract. It has a discovery partnership agreement with Eli Lilly and Company. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.
Financial Performance
Financial StatementsNews
AbCellera (ABCL), Everest to Co-Develop New Antibody Therapies
AbCellera (ABCL) partners with China-based Everest Medicines to expand the latter???s pipeline across multiple indications.
AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies
VANCOUVER, British Columbia and SHANGHAI, Sept. 22, 2021 /PRNewswire/ -- AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, "Everest") announced today that they have entered into a mu...
Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab...
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #AbCellera--Lilly to Supply the EU and EEA with up to 220,000 Doses of Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19
AbCellera Stock Is Moving Higher After Expanded Use Nod For Lilly-Partnered COVID-19 Antibody
The FDA has expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure prophylaxis in certain individuals to prevent SAR...
Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to ...
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #AbCellera--EUA of Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19
Why AbCellera Biologics Stock Jumped 7% on Wednesday
The company's drug-development technology is starting to attract attention.
AbCellera Shares Are Moving Higher On Licensing Pact With Moderna
AbCellera Biologics Inc (NASDAQ: ABCL) has entered into a research collaboration and license agreement with Moderna Inc (NASDAQ: MRNA) for antibodies for mRNA medicines. The collaboration will leverage ...
AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines
AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets
VANCOUVER, British Columbia & BOSTON--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets
AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference
VANCOUVER--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference
Here's Why AbCellera Biologics Stock Gained 10.6% Last Month
Even with its recent gains, the biotech stock is down roughly 53.4% in 2021's trading.
Why AbCellera Biologics Stock Was Up More Than 17% on Friday
The biopharma company's second quarter was better than expected. The future looks pretty bright, too.
AbCellera Reports Q2 2021 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Reports Q2 2021 Business Results
Is It Time to Buy 5 of the Nasdaq's Worst-Performing Stocks of 2021?
One particular group of stocks is overrepresented among the exchange's biggest losers this year. That's an important detail.
EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative Medicines
CAMBRIDGE, Mass. & VANCOUVER, British Columbia--(BUSINESS WIRE)--EQRx, a company committed to developing and delivering important new medicines at radically lower prices, and AbCellera (Nasdaq: ABCL), a...
Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Tr...
HOUSTON & VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Treatment...
AbCellera to Report Second Quarter 2021 Financial Results on August 12, 2021
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera (Nasdaq: ABCL) will announce its second quarter 2021 financial results on Thursday, August 12, 2021 and hold an earnings con...
AbCellera Appoints Neil Berkley as Chief Business Officer
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Appoints Neil Berkley as Chief Business Officer
AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing ...
VANCOUVER, British Columbia--(BUSINESS WIRE)-- #antibodies--AbCellera Continues Expansion & Strengthens Future Pandemic Preparedness with GMP Manufacturing Facility for Therapeutic Antibodies in Canada
AbCellera Announces Secondary Private Sale of 11.9 Million Common Shares
VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that certain entities owned and/or controlled, directly or indirectly, by Carl Hansen, Ph.D., Cofounder, Chief Exec...
CORRECTING and REPLACING AbCellera Reports Q1 2021 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Reports Q1 2021 Business Results
Why AbCellera Stock Crumbled Despite In-Line Royalties For Covid Drug
AbCellera stock tumbled Friday, despite in-line royalties for its Lilly-partnered Covid drug. Here's why the stock toppled.
AbCellera Reports Q1 2021 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Reports Q1 2021 Business Results
AbCellera to Present Virtually at Berenberg Conference on May 18, 2021
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera to Present Virtually at Berenberg Conference on May 18, 2021
AbCellera Partners with Angios to Develop Therapeutics to Combat Blindness Caused by Diabetic Retinopathy
VANCOUVER, British Columbia & INNSBRUCK, Austria--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Partners with Angios to Develop Therapeutics to Combat Blindness Caused by Diabetic Retinopathy